Merck Fails To Force Trial Of Bellwether Fosamax Case

Law360, New York (December 11, 2008, 12:00 AM EST) -- One of the bellwether plaintiffs in the multidistrict litigation over Merck & Co. Inc.'s osteoporosis drug Fosamax, who tried to drop her claims after Merck obtained a damaging deposition from one of her doctors, has finally gotten a judge's go-ahead to exit the MDL.

On Tuesday, Judge John F. Keenan of the U.S. District Court for the Southern District of New York granted a motion by Karen Denise Greene, one of three plaintiffs chosen for an early bellwether trial, to dismiss her own case.

Plaintiffs in...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.